Stockholm - Delayed Quote SEK

Cantargia AB (publ) (CANTA.ST)

1.6300

+0.0800

+(5.16%)

At close: May 9 at 5:29:55 PM GMT+2

Cantargia’s Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors

LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA) Results published in the peer-reviewed journal Investigational New Drugs Study in heavily pre-treated patients with solid tumor indications who had progressed on prior immune checkpoint ...

ACCESS Newswire 5 days ago

CANTA.ST
+5.16%
Invitation to the Presentation of Cantargia's Interim Report for Q1 2025

LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter of 2025 on Tuesday, May 13, 2025, at 07:00 a.m. CEST. In ...

ACCESS Newswire 12 days ago

CANTA.ST
+5.16%
Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10

LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment options CAN10 targets several pathways relevant for AD but distinct from ...

ACCESS Newswire 12 days ago

CANTA.ST
+5.16%
Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression

LUND, SE / ACCESS Newswire / April 28, 2025 / Cantargia (STO:CANTA) Preclinical data shows IL1 family signals mediate systemic immune suppression. Blocking IL1RAP can overcome resistance to immune therapy in a cervical cancer model. Clinical findings ...

ACCESS Newswire 13 days ago

CANTA.ST
+5.16%
Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate (ADC) at a Major Cancer Conference

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical models Anti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironment LUND, SWEDEN / ACCESS Newswire / April 25, ...

ACCESS Newswire 16 days ago

CANTA.ST
+5.16%
Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy (CIPN) at AACR

LUND, SE / ACCESS Newswire / April 25, 2025 / Cantargia (STO:CANTA) Clinical findings show association between nadunolimab and lower incidence and later onset of CIPN Preclinical data show prevention of both chemotherapy- and antibody-drug conjugate- ...

ACCESS Newswire 16 days ago

CANTA.ST
+5.16%
Cantargia Publishes Annual Report 2024

LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published. The Annual Report is attached to this press release and ...

ACCESS Newswire 30 days ago

CANTA.ST
+5.16%
Notice of Annual General Meeting in Cantargia AB (publ)

LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 15 May 2025, at 15.00 CEST at Ideon Gateway, Scheelevägen 27, Lund, Sweden. Right ...

ACCESS Newswire 30 days ago

CANTA.ST
+5.16%
Cantargia appoints Morten Lind Jensen as Chief Medical Officer

LUNDE, SE / ACCESS Newswire / April 1, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as Chief Medical Officer, effective immediately. "I am ...

ACCESS Newswire last month

CANTA.ST
+5.16%
Cantargia Publishes An Abstract On Parallel Anti-Tumor Activity And Reduction Of Chemotherapy-Induced Neuropathy With Nadunolimab

LUND, SWEDEN / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA) Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR clinical studies Potential neuroprotective effect further ...

ACCESS Newswire last month

CANTA.ST
+5.16%
Cantargia Presents Promising Preclinical Results on a Novel IL1RAP-Targeting Antibody-Drug Conjugate at AACR 2025

LUND, SE / ACCESS Newswire / March 25, 2025 /Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the development of IL1RAP-targeting antibody-drug conjugates ...

ACCESS Newswire last month

CANTA.ST
+5.16%
Cantargia to Participate at Van Lanschot Kempen’s Life Sciences Conference

LUND, SE / ACCESS Newswire / March 13, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that members of Cantargia's management will participate at the Van Lanschot Kempen Life Sciences Conference ...

ACCESS Newswire last month

CANTA.ST
+5.16%
First Patient Enrolled in Cantargia's Leukemia Study with nadunolimab

LUND, SE / ACCESS Newswire / March 12, 2025 / Cantargia (STO:CANTA) Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced that the first subject ...

ACCESS Newswire last month

CANTA.ST
+5.16%
Cantargia’s TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer Fully Recruited

TRIFOUR is Cantargia's first randomized, controlled study of nadunolimab First preliminary efficacy results expected mid-2025 LUND, SWEDEN / ACCESS Newswire / March 10, 2025 / Cantargia (Cantargia AB); (Nasdaq Stockholm:CANTA) today announced that ...

ACCESS Newswire 2 months ago

CANTA.ST
+5.16%
Cantargia to Participate at H.C. Wainwright’s Annual Autoimmune & Inflammatory Virtual Conference

LUND, SE / ACCESS Newswire / March 6, 2025 /Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory ...

ACCESS Newswire 2 months ago

CANTA.ST
+5.16%
Cantargia Reports Promising CAN10 Phase 1 Data From First Multiple Dose Cohort, and FDA and Key Opinion Leader Feedback

LUND, SE / ACCESS Newswire / March 5, 2025 / Cantargia (STO:CANTA) Promising multiple dose PK data continue to support 4-weekly dosing FDA advice received supporting phase 2 design in HS Strong Key Opinion Leader (KOL) support for CAN10 in HS Cantargia ...

ACCESS Newswire 2 months ago

CANTA.ST
+5.16%
Cantargia AB (STU:7V3) Q4 2024 Earnings Call Highlights: Strategic Shifts and Financial Insights

Cantargia AB (STU:7V3) reports reduced operating expenses, a successful rights issue, and strategic focus on immune-inflammatory assets amid management transition.

GuruFocus.com 2 months ago

7V3.SG
Cantargia Publishes Full Year Report for 2024

LUND, SWEDEN / ACCESS Newswire / February 21, 2025 / Cantargia (STO:CANTA) Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) full year report for 2024 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. ...

ACCESS Newswire 2 months ago

CANTA.ST
+5.16%
Cantargia to Participate in Leerink Partners Global Healthcare Conference

LUND, SE / ACCESS Newswire / February 19, 2025 /Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargia's management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference ...

ACCESS Newswire 2 months ago

CANTA.ST
+5.16%
Invitation to Presentation of Cantargia’s Year-End Report 2024

LUND, SE / ACCESSWIRE / February 13, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) invites investors, analysts and the press to a presentation of the interim October - December and Year-End report of 2024 at 3 pm (CET) ...

ACCESS Newswire 2 months ago

CANTA.ST
+5.16%

Performance Overview

Return	CANTA.ST	OMX Stockholm 30 Index (^OMX)
YTD	-3.55%	-1.38%
1-Year	-54.85%	-5.41%
3-Year	-83.09%	+27.89%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cantargia AB (publ) (CANTA.ST)

Cantargia’s Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors

Invitation to the Presentation of Cantargia's Interim Report for Q1 2025

Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10

Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression

Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate (ADC) at a Major Cancer Conference

Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy (CIPN) at AACR

Cantargia Publishes Annual Report 2024

Notice of Annual General Meeting in Cantargia AB (publ)

Cantargia appoints Morten Lind Jensen as Chief Medical Officer

Cantargia Publishes An Abstract On Parallel Anti-Tumor Activity And Reduction Of Chemotherapy-Induced Neuropathy With Nadunolimab

Cantargia Presents Promising Preclinical Results on a Novel IL1RAP-Targeting Antibody-Drug Conjugate at AACR 2025

Cantargia to Participate at Van Lanschot Kempen’s Life Sciences Conference

First Patient Enrolled in Cantargia's Leukemia Study with nadunolimab

Cantargia’s TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer Fully Recruited

Cantargia to Participate at H.C. Wainwright’s Annual Autoimmune & Inflammatory Virtual Conference

Cantargia Reports Promising CAN10 Phase 1 Data From First Multiple Dose Cohort, and FDA and Key Opinion Leader Feedback

Cantargia AB (STU:7V3) Q4 2024 Earnings Call Highlights: Strategic Shifts and Financial Insights

Cantargia Publishes Full Year Report for 2024

Cantargia to Participate in Leerink Partners Global Healthcare Conference

Invitation to Presentation of Cantargia’s Year-End Report 2024

Performance Overview